After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

In a landmark shift for consumer genomics, Anne Wojcicki, the co-founder and former CEO of 23andMe, has announced the ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt company’s assets.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech ... Under the deal, TTAM will acquire 23andMe’s signature “Personal Genome Service” ...

The prospect of 23andMe's trove of genetic information on millions of people passing to the highest bidder had sparked outcry ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.